We present a clinical case of de novo AML with concurrent BCR‐ABL1 and CBFB‐MYH11 rearrangements and discuss the diagnostic challenges, treatment implications, and prognostic implications. This evidence concerns the gene CBFB and acute myeloid leukemia.